Joshua Fitch is the senior editor for Contemporary Pediatrics. He joined the brand in March of 2023 as an editor before being promoted to senior editor in January 2024. Fitch graduated from Youngstown State University in Youngstown, Ohio in 2020 with a degree in telecommunications and journalism. He started his career as a news and sports videographer before becoming an on-air sports anchor at the NBC-affiliated news station in Youngstown. Fitch briefly worked as a national content writer for a Chicago-based national television station before joining the Contemporary Pediatrics team. He can be reached at: jfitch@mjhlifesciences.com.
Neffy pharmacokinetic profiles compared to epinephrine injections
February 23rd 2024Sarina Tanimoto, MD, MBA, breaks down a poster session regarding the pharmacokinetic profile of neffy, presented at the 2024 American Academy of Allergy, Asthma, & Immunology Annual Meeting in Washington DC from February 23 to February 26, 2024.
Neffy epinephrine nasal spray demonstrates positive data in repeat dosing study
February 21st 2024ARS Pharma plans to submit data from the repeat dose study of neffy to the FDA early in the second quarter of 2024, as part of its response to the CRL issued by the federal agency for the previously submitted New Drug Application (NDA).
Nirsevimab doses for 2024-2025 RSV season can be reserved with new program
February 2nd 2024Nirsevimab was approved by the FDA on July 17, 2023, ahead of the traditional RSV season, though in October, the Centers for Disease Control and Prevention (CDC) recommended it be prioritized for the highest-risk infants amid limited availability.
Quiz: Recommendations for influenza control in children from the American Academy of Pediatrics
February 1st 2024Take this quiz and test your knowledge of the American Academy of Pediatrics' recommendations for routine use of influenza vaccines, medications for the prevention and treatment of pediatric influenza.
Ibuprofen not linked to lower mortality, bronchopulmonary dysplasia risk in infants
January 30th 2024There are reports that prophylaxis with ibuprofen in the first 12 to 24 hours of life can reduce the risk of severe intraventricular hemorrhage and pulmonary hemorrhage. However, it has not been found to increase survival without neurosensory impairment at 18 months.